Dermatology

>

Latest News

Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study / image credit ©Brian Jackson/stock.adobe.com
Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study

February 21st 2024

AAAAI 2024. Reduction of AD signs and symptoms was significant among approximately half of study participants at 4 weeks and continuously rose through week 260, investigators report.

Tezepelumab Treatment Leads to Sustained Reductions in CSU Disease Activity, Inflammatory Markers / image credit hives; ©chomplearn/stock.adobe.com
Tezepelumab Demonstrates Sustained Post-Treatment Reductions in CSU Disease Activity, Inflammatory Markers

February 21st 2024

image credit pills money ©alex mlx/stock.adobe.com
Biden Administration Announces First 10 Prescription Drugs Slated for Price Negotiations

August 29th 2023

Friday's 5 Quotes for Primary Care: 3-24-2023
Friday's 5 Quotes for Primary Care: 3-24-2023

March 24th 2023

Seen in the ED: Lower Extremity Rash Resists Treatment
Seen in the ED: Lower Extremity Rash Resists Treatment

November 1st 2021

Latest CME Events & Activities

Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making

March 9, 2024

Register Now!

Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma

View More

Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis

View More

Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?

View More

"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation

View More

PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa

View More

Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care

View More

Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

View More

Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)

View More

Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

More News

© 2024 MJH Life Sciences

All rights reserved.